227 related articles for article (PubMed ID: 1851032)
21. Efficacy of oral ganciclovir in prevention of cytomegalovirus infection in post-kidney transplant patients.
Ahsan N; Holman MJ; Yang HC
Clin Transplant; 1997 Dec; 11(6):633-9. PubMed ID: 9408699
[TBL] [Abstract][Full Text] [Related]
22. Risk factors for Pneumocystis pneumonia after the first 6 months following renal transplantation.
Faure E; Lionet A; Kipnis E; Noël C; Hazzan M
Transpl Infect Dis; 2017 Oct; 19(5):. PubMed ID: 28608641
[TBL] [Abstract][Full Text] [Related]
23. Pneumocystis carinii pneumonia after renal transplantation.
Gupta RK; Jain M; Garg R
Indian J Pathol Microbiol; 2004 Oct; 47(4):474-6. PubMed ID: 16295369
[TBL] [Abstract][Full Text] [Related]
24. Solid organ transplantation: results and implications of acyclovir use in liver transplants.
Paya CV; Marin E; Keating M; Dickson R; Porayko M; Wiesner R
J Med Virol; 1993; Suppl 1():123-7. PubMed ID: 8245877
[TBL] [Abstract][Full Text] [Related]
25. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
26. Pneumocystis pneumonia in solid organ transplant recipients: not yet an infection of the past.
Wang EH; Partovi N; Levy RD; Shapiro RJ; Yoshida EM; Greanya ED
Transpl Infect Dis; 2012 Oct; 14(5):519-25. PubMed ID: 22571389
[TBL] [Abstract][Full Text] [Related]
27. Reassessing the impact of cytomegalovirus infection in kidney and kidney-pancreas transplantation.
Becker BN; Becker YT; Leverson GE; Simmons WD; Sollinger HW; Pirsch JD
Am J Kidney Dis; 2002 May; 39(5):1088-95. PubMed ID: 11979354
[TBL] [Abstract][Full Text] [Related]
28. Multicenter evaluation of efficacy and safety of low-dose versus high-dose valganciclovir for prevention of cytomegalovirus disease in donor and recipient positive (D+/R+) renal transplant recipients.
Heldenbrand S; Li C; Cross RP; DePiero KA; Dick TB; Ferguson K; Kim M; Newkirk E; Park JM; Sudaria-Kerr J; Tichy EM; Ueda KR; Weng R; Wisniewski J; Gabardi S
Transpl Infect Dis; 2016 Dec; 18(6):904-912. PubMed ID: 27639246
[TBL] [Abstract][Full Text] [Related]
29. Concurrent Pneumocystis carinii and cytomegalovirus pneumonia after autologous peripheral blood stem cell transplantation.
Chuu WM; Catlett JP; Perry DJ; Geddes LG; Levit PD; Levy CS; Buick MK; Malkovska V
Bone Marrow Transplant; 1999 May; 23(10):1087-9. PubMed ID: 10373078
[TBL] [Abstract][Full Text] [Related]
30. A comparative randomised study of valacyclovir vs. oral ganciclovir for cytomegalovirus prophylaxis in renal transplant recipients.
Pavlopoulou ID; Syriopoulou VP; Chelioti H; Daikos GL; Stamatiades D; Kostakis A; Boletis JN
Clin Microbiol Infect; 2005 Sep; 11(9):736-43. PubMed ID: 16104989
[TBL] [Abstract][Full Text] [Related]
31. Aerosolized pentamidine as alternative primary prophylaxis against Pneumocystis carinii pneumonia in adult hepatic and renal transplant recipients.
Saukkonen K; Garland R; Koziel H
Chest; 1996 May; 109(5):1250-5. PubMed ID: 8625676
[TBL] [Abstract][Full Text] [Related]
32. Intravenous immunoglobulin prophylaxis of cytomegalovirus infection in pediatric renal transplant recipients.
Flynn JT; Kaiser BA; Long SS; Schulman SL; Deforest A; Polinsky MS; Baluarte HJ
Am J Nephrol; 1997; 17(2):146-52. PubMed ID: 9096445
[TBL] [Abstract][Full Text] [Related]
33. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
34. Infections following orthotopic liver transplantation.
Arnow PM
HPB Surg; 1991 Apr; 3(4):221-32; discussion 232-3. PubMed ID: 1650245
[TBL] [Abstract][Full Text] [Related]
35. Risk factors and impact of cytomegalovirus disease in simultaneous pancreas-kidney transplantation.
Kaufman DB; Leventhal JR; Gallon LG; Parker MA; Koffron AJ; Fryer JP; Abecassis MM; Stuart FP
Transplantation; 2001 Dec; 72(12):1940-5. PubMed ID: 11773893
[TBL] [Abstract][Full Text] [Related]
36. A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients.
Flechner SM; Avery RK; Fisher R; Mastroianni BA; Papajcik DA; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
Transplantation; 1998 Dec; 66(12):1682-8. PubMed ID: 9884259
[TBL] [Abstract][Full Text] [Related]
37. Management and prevention of cytomegalovirus infection after renal transplantation.
Farrugia E; Schwab TR
Mayo Clin Proc; 1992 Sep; 67(9):879-90. PubMed ID: 1331630
[TBL] [Abstract][Full Text] [Related]
38. Prophylactic ganciclovir treatment reduces fungal as well as cytomegalovirus infections after heart transplantation.
Wagner JA; Ross H; Hunt S; Gamberg P; Valantine H; Merigan TC; Stinson EB
Transplantation; 1995 Dec; 60(12):1473-7. PubMed ID: 8545877
[TBL] [Abstract][Full Text] [Related]
39. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis against herpes infections in kidney transplant patients with special emphasis on CMV.
Birkeland SA; Andersen HK; Gahrn-Hansen B
Scand J Infect Dis; 1998; 30(3):221-6. PubMed ID: 9790127
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
